Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The person has been diagnosed with invasive breast cancer confirmed by tissue testing.
- The cancer is at a locally advanced stage (larger tumour or spread to nearby lymph nodes, but not to distant parts of the body), and is either a hormone-sensitive type (HER2-negative) or triple-negative type, and the tumour did not shrink by more than 50% after 2 cycles of chemotherapy given before surgery.
- The person is generally in good health overall, with organs functioning well enough and no serious uncontrolled health problems (confirm with trial site for specific thresholds).
- The person is able to have an MRI scan.
- The person is able to attend follow-up appointments after the trial.
- The person has agreed to take part and signed a consent form.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- The person is currently pregnant.
- The person has breast cancer in both breasts at the same time.
- The person has previously had radiotherapy to the chest wall.
- The person has an active connective tissue disease (such as lupus or scleroderma — confirm with trial site).
- The person has inflammatory breast cancer.
- The person has a large breast volume (over 600ml) or a BMI over 30.
- The person has diabetes.
- Cancer has spread to lymph nodes above or below the collarbone, or to lymph nodes behind the breastbone.
- The person is currently using immunotherapy drugs such as PD-1 or PD-L1 inhibitors.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jing Jin, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phone: +86-18674776996
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
pathological complete respons
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.